STOCK TITAN

ChromaDex Corporation - $CDXC STOCK NEWS

Welcome to our dedicated page for ChromaDex Corporation news (Ticker: $CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ChromaDex Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ChromaDex Corporation's position in the market.

Rhea-AI Summary

ChromaDex (NASDAQ:CDXC) reported first quarter 2024 financial results with total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million, and positive Adjusted EBITDA of $0.7 million. The company reiterated a full-year outlook with net sales growth of at least 16%. Tru Niagen® contributed $17.4 million to total net sales, and ChromaDex expanded distribution through partnerships with The Vitamin Shoppe and Sprouts Farmers Market. Operating expenses decreased, net loss improved, and Adjusted EBITDA turned positive. The company aims for revenue growth, gross margin improvement, and increased investments in research and development, marketing, and product launches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

ChromaDex announces an ingredient partnership with Solgar, a Nestlé Health Science brand, introducing Solgar Cellular Energy supplement featuring ChromaDex's NIAGEN NR. The collaboration aims to boost NAD+ levels for cellular health, highlighting NIAGEN as the gold standard in NAD+ supplements. NIAGEN NR, supported by extensive research, increases NAD+ by over 50% in two weeks. Solgar Cellular Energy also includes B vitamins and vitamin C for comprehensive health benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
Rhea-AI Summary
ChromaDex announces the nationwide launch of Tru Niagen® at The Vitamin Shoppe®, making the NAD+ supplement available at 700 retail locations and online. Tru Niagen features NIAGEN®, the most efficient NAD+ precursor, supported by Nobel Prize winners and extensive clinical studies, emphasizing cellular health, recovery, and vitality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will report its first quarter 2024 financial results on May 8, 2024. The company specializes in NAD+ and healthy aging research. An investor conference call will be held to discuss the results and provide a business update. The call will take place at 4:30 p.m. ET on May 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the major grocery debut of Tru Niagen® at Sprouts Farmers Market, expanding its reach to health-conscious consumers in over 400 locations across 23 states. Tru Niagen®, the top NAD+ supplement for healthy aging in the US, is now available at Sprouts, showcasing ChromaDex's commitment to enhancing access to its products. The partnership with Sprouts aligns with ChromaDex's goal of transforming the aging process for a broader audience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.25%
Tags
none
-
Rhea-AI Summary
ChromaDex Corp. announces that its Tru Niagen product line is now third-party verified through the Alkemist Assured program, ensuring quality and transparency in the dietary supplement industry. The company's commitment to excellence and consumer trust is reinforced by this partnership, setting a new industry standard for product verification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) reported strong financial results for the fourth quarter and full year 2023, with net sales of $21.2 million and $83.6 million, respectively. The company achieved positive net income, gross margin improvements, and positive adjusted EBITDA. Key highlights include the launch of Tru Niagen® Pro 1,000 mg and successful clinical trials showcasing the benefits of Niagen® in various health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
-
Rhea-AI Summary
ChromaDex Corp. (CDXC) schedules a conference call to discuss fourth-quarter 2023 financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences earnings
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on Monday, February 12, 2024, at 11:00 AM PST. The event will feature the latest investor presentation by CEO Rob Fried and CFO Brianna Gerber, followed by a live Q&A. Registration is limited, but the replay will be available on ChromaDex’s website. For more information, visit www.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) CEO and CFO will be participating in the Lytham Partners 2024 Investor Select Conference for virtual one-on-one meetings. The event is scheduled for Thursday, February 1, 2024. For more information, visit www.chromadex.com and www.investors.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
ChromaDex Corporation

Nasdaq:CDXC

CDXC Rankings

CDXC Stock Data

289.26M
51.40M
41.19%
16.13%
1.75%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
LOS ANGELES

About CDXC

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).